 Low-dose cyclopenthiazide treatment hypertension one-year community-based study placebo period patients diastolic blood pressures mmHg micrograms low dose micrograms cyclopenthiazide standard dose period year Blood pressure patient home observer two-weekly intervals placebo run-in period weeks weeks weeks Serum potassium urate glucose glycosylated haemoglobin total HDL cholesterol apolipoproteins end placebo period weeks active treatment patients inadequate antihypertensive response dose dose patient micrograms adverse effects patients systolic diastolic blood pressures pretreatment values treatment groups year period decreases blood pressure different patients micrograms potassium supplements Maximum decreases serum potassium mmol/l micrograms mmol/l micrograms weeks treatment patients differences doses time significant increases serum urate weeks